Spotlight On... Huennekens details employee strategy at Verb Surgical as staff hits 65; Hologic rolls out uterine tissue collection device; Startup nabs Expedited tag from FDA for lung system;

The robotic surgery and device JV--from Google parent company Alphabet ($GOOG) and Johnson & Johnson ($JNJ), spinoff Verb Surgical--is aiming for a culture similar to Google's. At the recent Medical Device Manufacturers Association (MDMA) annual meeting in Washington, DC, the president and CEO of Verb, Scott Huennekens, said that he's aiming for a culture similar to Google. He had those at a leadership team meeting submit business cards, only to dramatically throw them out. "We're just going to have to be one team if this is going to work. It doesn't matter what your business card says. We're in this one project together,'" Huennekens said according to coverage in MD+DI. He was the chairman of MDMA. More

> Hologic ($HOLX) has launched its MyoSure Reach device to enable physicians to reach the upper third of the uterine cavity to conduct tissue removal for pathology testing. More

> British Columbia startup Lungpacer Medical has received Expedited Access Pathway designation from the FDA for its Lungpacer Diaphragm Pacing System to treat patients who have been unable to wean from mechanical ventilation. More

> Proton therapy player Varian Medical Systems ($VAR) has started to equip HollandPTC in Delft with a proton therapy system for precision cancer therapy with fewer side effects. More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.